Oculis Holding AG (OCS) Total Debt (2021 - 2022)
Oculis Holding AG (OCS) posted quarterly Total Debt of $127.1 million for Q4 2022, up 3.26% year-over-year from $123.1 million in Q4 2021, and up 3.26% quarter-over-quarter from $123.1 million in Q4 2021.
Oculis Holding AG (OCS) Total Debt (2021 - 2022) Analysis & Trends
Oculis Holding AG's Total Debt history runs 2 years deep, the most recent figure standing at $127.1 million for Q4 2022.
- In Q4 2022, Total Debt rose 3.26% year-over-year to $127.1 million; the TTM figure through Dec 2022 stood at $127.1 million (up 3.26% YoY), while the FY2022 annual figure was $128.4 million, up 3.34% from the prior year.
- Total Debt for Q4 2022 stood at $127.1 million, up from $123.1 million in the prior quarter.
- The five-year high for Total Debt was $127.1 million in Q4 2022, with the low at $123.1 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 127.10 Mn |
| Dec 31, 2021 | 123.09 Mn |